Safety and tolerability in the OPTIMA study were consistent with previous data for OPSUMIT in
combination with a PDE-5i.1
Median (interquartile range) exposure to the study treatment was 86.5 (53.0, 115.1) weeks.1
 Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020 Sep 3;56 (3):2000673.
 Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015 Dec;46 (6):1711-20.
 Ministry of health Opsumit approved insert leaflet 15/10/2018.